Nuvigil (armodafinil tablets) is expected to be made available by Cephalon on June 1, 2009. Nuvigil is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), narcolepsy, and shift work sleep disorders (SWD). In OSAHS, Nuvigil is indicated as an adjunct to standard treatments for the underlying obstruction.
Nuvigil will be available in 50mg, 150mg, and 250mg dosage strengths.
For more information call (800) 896-5855 or visit www.nuvigil.com.